{"certainAgreement":{"otherDetails":"The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The study was planned to be conducted in 3 parts and was discontinued early after the completion of Part 1A due to strategic reasons. No participants enrolled into Parts 1B and 2."},"pointOfContact":{"email":"medinfo@amgen.com","organization":"Amgen Inc.","phone":"866-572-6436","title":"Study Director"}}